Cargando…
Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists †
Majority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number of chiral, non-racemic drugs on the market is increasing, and it is becoming ever more important...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822454/ https://www.ncbi.nlm.nih.gov/pubmed/36615465 http://dx.doi.org/10.3390/molecules28010271 |
_version_ | 1784865950186602496 |
---|---|
author | Reyes, Efraim Prieto, Liher Milelli, Andrea |
author_facet | Reyes, Efraim Prieto, Liher Milelli, Andrea |
author_sort | Reyes, Efraim |
collection | PubMed |
description | Majority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number of chiral, non-racemic drugs on the market is increasing, and it is becoming ever more important to prepare these compounds in a safe, economic, and environmentally sustainable fashion. Asymmetric organocatalysis has a long history, but it began its renaissance era only during the first years of the millennium. Since then, this field has reached an extraordinary level, as confirmed by the awarding of the 2021 Chemistry Nobel Prize. In the present review, we wish to highlight the application of organocatalysis in the synthesis of enantio-enriched molecules that may be of interest to the pharmaceutical industry and the medicinal chemistry community. We aim to discuss the different activation modes observed for organocatalysts, examining, for each of them, the generally accepted mechanisms and the most important and developed reactions, that may be useful to medicinal chemists. For each of these types of organocatalytic activations, select examples from academic and industrial applications will be disclosed during the synthesis of drugs and natural products. |
format | Online Article Text |
id | pubmed-9822454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98224542023-01-07 Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † Reyes, Efraim Prieto, Liher Milelli, Andrea Molecules Review Majority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number of chiral, non-racemic drugs on the market is increasing, and it is becoming ever more important to prepare these compounds in a safe, economic, and environmentally sustainable fashion. Asymmetric organocatalysis has a long history, but it began its renaissance era only during the first years of the millennium. Since then, this field has reached an extraordinary level, as confirmed by the awarding of the 2021 Chemistry Nobel Prize. In the present review, we wish to highlight the application of organocatalysis in the synthesis of enantio-enriched molecules that may be of interest to the pharmaceutical industry and the medicinal chemistry community. We aim to discuss the different activation modes observed for organocatalysts, examining, for each of them, the generally accepted mechanisms and the most important and developed reactions, that may be useful to medicinal chemists. For each of these types of organocatalytic activations, select examples from academic and industrial applications will be disclosed during the synthesis of drugs and natural products. MDPI 2022-12-29 /pmc/articles/PMC9822454/ /pubmed/36615465 http://dx.doi.org/10.3390/molecules28010271 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Reyes, Efraim Prieto, Liher Milelli, Andrea Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † |
title | Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † |
title_full | Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † |
title_fullStr | Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † |
title_full_unstemmed | Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † |
title_short | Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists † |
title_sort | asymmetric organocatalysis: a survival guide to medicinal chemists † |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822454/ https://www.ncbi.nlm.nih.gov/pubmed/36615465 http://dx.doi.org/10.3390/molecules28010271 |
work_keys_str_mv | AT reyesefraim asymmetricorganocatalysisasurvivalguidetomedicinalchemists AT prietoliher asymmetricorganocatalysisasurvivalguidetomedicinalchemists AT milelliandrea asymmetricorganocatalysisasurvivalguidetomedicinalchemists |